
EGFR-IN-87
CAS No. 1835666-87-9
EGFR-IN-87( —— )
Catalog No. M37255 CAS No. 1835666-87-9
EGFR-IN-87 is a potent EGFR tyrosine kinase inhibitor with anticancer activity that inhibits EGFR_d746-750, EGFR_L858R/T790M, and EGFR_WT in A431 cells, and can be used for cancer research.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 459 | Get Quote |
![]() ![]() |
10MG | 657 | Get Quote |
![]() ![]() |
25MG | 994 | Get Quote |
![]() ![]() |
50MG | 1371 | Get Quote |
![]() ![]() |
100MG | 1773 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEGFR-IN-87
-
NoteResearch use only, not for human use.
-
Brief DescriptionEGFR-IN-87 is a potent EGFR tyrosine kinase inhibitor with anticancer activity that inhibits EGFR_d746-750, EGFR_L858R/T790M, and EGFR_WT in A431 cells, and can be used for cancer research.
-
DescriptionEGFR-IN-87 is a EGFR tyrosine kinase inhibitor. EGFR-IN-87 has IC50 value of 3.1 nM, 1.3 nM and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790 and EGFR_WT in A431 cells, respectively. EGFR-IN-87 can be used for cancer diseases research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetTyrosinase
-
RecptorTyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1835666-87-9
-
Formula Weight499.61
-
Molecular FormulaC28H33N7O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C=C)NC1=CC(NC2=NC=CC(=N2)N3C=C(C=4C=CC=CC43)C)=C(OC)C=C1N(C)CCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Song Y.T, et al. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase. The United States, WO2017120429 A1. 2017-07-13.
molnova catalog



related products
-
Citraconic acid
Citraconic acid is a dicarboxylic acid consisting of maleic acid having a methyl substituent at the 2-position.
-
(Z)-SU14813
(Z)-SU14813 is a novel tyrosine kinase inhibitor with anticardiogenic and antitumor activity that inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent manner.
-
EHT 1610
EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.